Estonia Investigates Novo Nordisk Over Suspected Illegal Drug Promotion Campaign

In Estonia, a campaign by Novo Nordisk, the pharmaceutical giant behind the popular weight-loss drug Ozempic, has drawn scrutiny. The initiative reportedly guides individuals toward private clinics that discuss weight-loss medications, sparking questions about its true nature.

While the campaign's focus is on weight reduction, Novo Nordisk maintains it does not constitute official advertising for prescription drugs. This distinction has led to concerns that the campaign may be a subtle, yet potentially illegal, method of promoting its products, particularly given the high demand for such medications in Europe.

Estonian authorities are reportedly investigating the matter to determine if the campaign violates regulations concerning pharmaceutical advertising. The situation highlights the complex regulatory landscape surrounding the marketing of weight-loss drugs and the potential for companies to employ indirect strategies to reach consumers.